Professor Michael A. Nauck, MD, Dr. h.c.

Diabetes Division, Katholisches Klinikum Bochum gGmbH, St. Josef-Hospital, Ruhr-University, Bochum, Germany

Michael Nauck is Head of Clinical Research at the Diabetes Division of St. Josef-Hospital (Ruhr-University Bochum) in Bochum, Germany.

Professor Nauck has a particular research interest in the role of gastrointestinal peptide hormones (incretins: glucose-dependent insulinotropic polypeptide, GIP, and glucagon-like peptide-1, GLP-1) in the physiological regulation of metabolism and in the pathophysiology of type 2 diabetes. He has contributed pivotal studies proving a therapeutic potential of GLP-1 in type 2 diabetes. He has contributed to the development of incretin-based glucose-lowering medications such as GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase-4. Additional areas of interest include spontaneous hypoglycaemia (insulinomas), pancreas transplantation, cardiovascular complications of type 2 diabetes, and the modification of cardiovascular risk in type 2-diabetic patients with glucose-lowering pharmacotherapy. His scientific contributions have been honoured with several awards, including the Ferdinand-Bertram Award (1993), the Werner-Creutzfeldt Award (2007) and the Paul Langerhans Medal (2012) from the German Diabetes Association, and the Claude Bernard Medal from the European Association for the Study of Diabetes (2022).

He has served as reviewer for all major diabetes journals and has published more than 245 original articles and 130 reviews and book chapters. His publications have been quoted > 84000 times, his “H-index” is 108, and he has been a “highly-cited researcher” (among the top 1 %) in 2019 (Web of Knowledge). Professor Nauck is member of a number of professional societies, including the German, European, American Diabetes Associations, and the International Diabetes Federation.